Is ResMed Stock A Trap Or A Missed Opportunity?

robot
Abstract generation in progress

ResMed (RMD) stock is currently trading at an attractive valuation, supported by strong fundamentals including accelerating recurring revenue from its Masks & Accessories segment, high margins, and a low-debt capital structure. The company benefits from a powerful moat due to its proprietary AirView software and market share gains from a competitor’s recall. However, the investment debate is centered on the potential structural threat of GLP-1 drugs impacting its total addressable market for sleep apnea.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)